Jon E. Chatterton
54Patents
6h-index
21Co-inventors
72Inventor score
Filing activity: Aug 16, 2002 → Aug 17, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8940887B2 | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis | Chemistry; Metallurgy | 32 | Active |
| US7947660B2 | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma | Chemistry; Metallurgy | 31 | Active |
| US8173617B2 | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma | Chemistry; Metallurgy | 31 | Active |
| US7592324B2 | RNAi-mediated inhibition of ocular targets | Chemistry; Metallurgy | 15 | Active |
| US7973019B1 | Transferrin/transferrin receptor-mediated siRNA delivery | Chemistry; Metallurgy | 13 | Active |
| US7879813B2 | Interfering RNA delivery system and uses thereof | Human Necessities | 11 | Active |
| US8017592B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 4 | Active |
| US9289514B2 | Low density lipoprotein receptor-mediated siRNA delivery | Chemistry; Metallurgy | 3 | Active |
| US8399653B2 | Transferrin/transferrin receptor-mediated siRNA delivery | Chemistry; Metallurgy | 3 | Active |
| US8268798B2 | Low density lipoprotein receptor-mediated siRNA delivery | Chemistry; Metallurgy | 3 | Active |
| US8664375B2 | Interfering RNA delivery system and uses thereof | Human Necessities | 2 | Active |
| US11008548B2 | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) | Chemistry; Metallurgy | 2 | Active |
| US8222227B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 2 | Active |
| US8937051B2 | Low density lipoprotein receptor-mediated siRNA delivery | Chemistry; Metallurgy | 2 | Active |
| US8673873B1 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders | Chemistry; Metallurgy | 1 | Active |
| US11186822B2 | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) | Chemistry; Metallurgy | 1 | Active |
| US9206428B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 1 | Active |
| US9526799B2 | Low density lipoprotein receptor-mediated siRNA delivery | Chemistry; Metallurgy | 1 | Active |
| US11453861B2 | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) | Chemistry; Metallurgy | 1 | Active |
| US11384335B2 | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) | Chemistry; Metallurgy | 1 | Active |
| US8618278B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 1 | Active |
| US7981870B2 | RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesis | Chemistry; Metallurgy | 1 | Active |
| US9476047B2 | RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions | Chemistry; Metallurgy | 1 | Active |
| US7732421B2 | RNAI-mediated inhibition of tumor necrosis factor α-related conditions | Chemistry; Metallurgy | 1 | Active |
| US8048863B2 | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.